Endometrial pathology and estrogens.
Endometrial biopsies were obtained from 46 hypogonadal patients (44 with gonadal dysgenesis; 2 panhypopituitary) who were receiving estrogen-progestogen therapy. Endometrial abnormalities occurred only in patients receiving a total lifetime conjugated estrogen dose of greater than or equal to 2500 mg and who had received estrogen treatment for a period longer than 4.2 years. The biopsy outcome was significantly related (P less than 0.01) to the estrogen dose at time of biopsy and to the total lifetime dose (P less than 0.05). The progestational drugs administered did not protect against development of endometrial abnormalities. None of the abnormal endometrial patterns were associated with abnormal vaginal bleeding.
D000293:Adolescent; D000328:Adult; D001706:Biopsy; D004714:Endometrial Hyperplasia / Q000139:chemically induced* / Q000235:genetics / Q000473:pathology; D004717:Endometrium / Q000473:pathology*; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007621:Karyotyping; D008875:Middle Aged; D014424:Turner Syndrome / Q000188:drug therapy
D004966:Estrogens, Conjugated (USP)